



**REGISTERED OFFICE**

**GRANULES INDIA LTD.**, 2nd Floor, 3rd Block, My Home Hub,  
Madhapur, Hyderabad - 500 081, Telangana, INDIA.  
Tel: +91 40 30660000, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com  
CIN: L24110TG1991PLC012471

**Dated October 29, 2018**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES; BSE: 532482

**Sub: Granules Pharmaceuticals, Inc. completed U.S. FDA inspection.**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir,


Please be informed that, Granules Pharmaceuticals, Inc., the wholly-owned foreign subsidiary of the Company located at Chantilly, Virginia, USA, has completed US FDA inspection from 22<sup>nd</sup> October 2018 to 26<sup>th</sup> October 2018 with two Form 483 observations. Granules Pharmaceuticals, Inc. will respond to the observations within this week. This was a prior approval inspection, intended for the ANDAs filed by Granules Pharmaceuticals, Inc. This facility is involved in development and manufacturing of Finished Dosages.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours faithfully,

**For GRANULES INDIA LIMITED**

*T. Chaitanya*  


**CHAITANYA TUNMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**